Expertise in
29
conditions

Dr. John Hausdorff

Radiation Oncology
Montage Medical Group, Specialty Services
23845 Holman Hwy Ste 210, 
Monterey, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
29
conditions
Montage Medical Group, Specialty Services
23845 Holman Hwy Ste 210, 
Monterey, CA 

Overview

John Hausdorff is a Radiation Oncologist in Monterey, California. Dr. Hausdorff is highly rated in 29 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Paget Disease of the Breast.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Pediatrics in CA

Hospital Affiliations

Community Hospital Of The Monterey Peninsula
Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Montage Medical Group, Specialty Services
23845 Holman Hwy Ste 210, Monterey, CA 93940

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

3 Total Publications

Getting by with a Little Help from Our Friends.
Getting by with a Little Help from Our Friends.
Journal: Journal of palliative medicine
Published: April 02, 2021
Similar Doctors
Expertise in
15
conditions
Dr. Richard Hoppe
Radiation Oncology
Expertise in
15
conditions
Dr. Richard Hoppe
Radiation Oncology

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (61.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Richard Hoppe is a Radiation Oncologist in Palo Alto, California. Dr. Hoppe is highly rated in 15 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Mycosis Fungoides, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Cutaneous T-Cell Lymphoma (CTCL).

Expertise in
9
conditions
Dr. Maximilian Diehn
Radiation Oncology
Expertise in
9
conditions
Dr. Maximilian Diehn
Radiation Oncology

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (61.1 miles away)
650-723-6171
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maximilian Diehn is a Radiation Oncologist in Palo Alto, California. Dr. Diehn is highly rated in 9 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
45
conditions
Dr. Scott Soltys
Radiation Oncology
Expertise in
45
conditions
Dr. Scott Soltys
Radiation Oncology

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (61.1 miles away)
650-724-1569
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Soltys is a Radiation Oncologist in Palo Alto, California. Dr. Soltys is highly rated in 45 conditions, according to our data. His top areas of expertise are Metastatic Brain Tumor, Brain Tumor, Astrocytoma, Meningioma, and Rhizotomy.

Frequently Asked Questions about Dr. John Hausdorff

How do I make an appointment with Dr. John Hausdorff?

You can book an appointment with Dr. John Hausdorff by calling their office at 831-620-0700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Hausdorff a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Hausdorff is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Hausdorff specialize in?

While Dr. John Hausdorff is a Radiation Oncology, they have specific expertise in Colorectal Cancer, Lynch Syndrome, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. John Hausdorff participate in research or clinical trials?

Yes. Dr. John Hausdorff has published 3 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. John Hausdorff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John Hausdorff accept my insurance?

Dr. John Hausdorff accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 831-620-0700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hausdorff's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 71 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile